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ABSTRACT
Objectives To understand attitudes towards infertility 
and willingness to pay (WTP) towards a publicly 
funded national assistive reproductive therapies (ART) 
programme.
Design Attitudes survey with dichotomous and open- 
ended WTP questions.
Setting Online survey administered in the USA, UK, 
Norway, Sweden, Finland, Denmark and China.
Participants 7945 respondents, analysed by country. 
Nordic respondents were pooled into a regionally 
representative sample.
Primary and secondary outcome measures Primary 
outcome measures were proportion of sample agreeing 
with different infertility- related and ART- related value 
statements and supporting a monthly contribution to 
fund a national ART programme, expressed in local 
currency. Secondary outcome measure was maximum 
WTP.
Results Across the nationally representative samples, 
75.5% of all respondents agreed with infertility as a 
medical condition and 82.3% and 83.7% with ART 
eligibility for anyone who has difficulty having a baby or 
a medical problem preventing them from having a baby, 
respectively. 56.4% of respondents supported a defined 
monthly contribution and 73.9% supported at least some 
additional contribution to fund a national ART programme. 
Overall, converting to euros, median maximum WTP was 
€3.00 and mean was €15.47 (95% CI 14.23 to 16.72) per 
month. Maximum WTP was highest in China and the USA 
and lowest in the European samples.
Conclusions This large, multicountry survey extends 
our understanding of public attitudes towards infertility 
and fertility treatment beyond Europe. It finds evidence 
that a majority of the public in all sampled countries/
regions views infertility as a treatable medical condition 
and supports the idea that all infertile individuals should 
have access to treatments that improve the chance of 
conception. There was also strong agreement with the 
idea that the desire for children is a basic human need. 
WTP questions showed that a majority of respondents 
supported a monthly contribution to fund a national 
ART programme, although there is some evidence of an 
acquiescence bias that may overstate support among 
specific samples.
INTRODUCTION
Data from the Organisation for Economic 
Co- operation and Development (OECD) 
show that global fertility rates have been 
declining steadily over the past 50 years to 
the point that they are now below population 
replacement levels in most OECD countries.1 
Theories explaining the cause of this decline 
tend to centre on the demographic transition 
from high- birth, high- mortality rates to low- 
birth, low- mortality rates in most countries, 
which is associated with delays in marriage 
and childbearing and smaller families rela-
tive to pretransition levels.2 3 Delays in child-
bearing, along with population health trends 
including increasing obesity rates, a rise of 
sexually transmitted diseases and evidence 
of decreasing sperm quality,4 means that an 
increasing number of prospective parents are 
experiencing some degree of infertility.5 6
Strengths and limitations of this study
 ► The survey elicits attitudes towards infertility and 
fertility treatment and presents a dichotomous will-
ingness to pay (WTP) question, limiting anchoring ef-
fects and extreme responses, as well as a maximum 
WTP question across five countries/regions.
 ► The dichotomous WTP amount was based on rough 
estimates of per- capita costs of a national fertility 
treatment programme in each country, but these 
should not be taken as a definitive estimate of the 
cost of fertility treatment in each country.
 ► Responses to attitudinal and WTP questions were 
descriptively summarised by country but not anal-
ysed for significant differences between countries, 
as the study design cannot account for potentially 
important cultural and health system differences 
between the countries.
 ► The top 1% of maximum WTP responses from each 
country/region were excluded from the Tobit analy-
sis to moderate the effect of any extreme or ‘protest’ 
responses.
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Boivin et al6 reviewed the studies of the prevalence of 
infertility and found 12- month infertility rates ranging 
from 3.5% to 16.7% in more developed countries. They 
also found that although an average of 56.1% of infer-
tile individuals/couples sought medical care, only 22.4% 
actually received care. This gap highlights the barriers to 
patient access to fertility treatments, more specifically 
known as assistive reproductive therapies (ART).
As fertility rates decline, the proportion of elderly 
citizens in a population grows, leading to skewed popu-
lation demographics, potential labour shortages and 
an increasing dependency ratio leading to increasing 
burdens on working age adults to maintain existing 
public services and benefits.7 To address declining 
fertility rates, governments are increasingly consid-
ering different elements of a ‘population policy mix’, 
including promoting access to ART for infertile individ-
uals/couples.5 7 However, evidence on public support for 
national ART programmes, particularly in terms of will-
ingness to pay (WTP), is limited. A key study by Rauprich 
et al8 in Germany found that more than three- quarters of 
all respondents supported full or partial public coverage 
of ART, including respondents identifying as patients, 
reproductive care physicians, medical ethicists, social 
lawyers, ‘health politicians’ and the general public. They 
also reported that 57% of the general public (n=1005) 
supported a hypothetical €1.50 per month increase in 
healthcare insurance premiums to fund a national ART 
programme in Germany. Support for public funding was 
strongly associated with views of infertility as a disease; 
that there is a need for assisted reproduction for infertile 
couples; and that every human should have the opportu-
nity to have children.
A multicountry survey of public attitudes towards ART 
was conducted by Fauser et al9 in six European countries 
(France, Germany, Italy, Spain, Sweden, UK; n=6110). 
Overall, they found that 93% of respondents supported 
at least one publicly funded cycle of ART and up to six 
or more funded cycles, with support peaking at between 
two and three cycles (28% and 23% of all respondents, 
respectively), although this support was not elicited in 
the context of a specific taxpayer contribution. Based 
on the substantial difference between general ‘support’ 
and a specific WTP observed by Rauprich et al,8 it is likely 
public WTP for such a programme will be lower than this 
general support. Other studies have explored patient 
WTP for ART,10–14 but a patient perspective is less useful 
than a public perspective when considering the value of a 
taxpayer- funded programme.
In this study, we sought to build on the results of 
Rauprich et al8 by seeking to understand public support 
and WTP for a nationally funded ART programme in five 
countries/regions: USA, UK, Spain, China and the Nordic 
region. In the following sections, we describe the meth-
odology and results of a survey of nationally representa-
tive samples, including attitudes towards infertility and 
eligibility for ART and WTP a country- specific monthly 
contribution towards a national ART programme. We 
find that support for this contribution varies by country 




The online survey was administered in two parts. In the 
first part, a nationally representative sample of respon-
dents were asked about their demographic character-
istics, including age, income and any experience with 
infertility or ART treatment, as well as their attitudes 
towards infertility and fertility treatment. Respondents 
indicated agreement or disagreement with a series of 
statements about infertility and different ART eligibility 
criteria. Following these, respondents were asked to 
indicate their WTP a country- specific contribution each 
month to fund a national ART programme. In a follow- up 
question, respondents were asked the maximum amount 
they would be willing to pay as an open- ended question. 
Respondents who were not willing to pay the presented 
amount were constrained to an amount between zero 
and the threshold amount. Respondents who were willing 
to pay the presented amount were constrained to an 
amount greater than this figure.
The country- specific monthly contribution was calcu-
lated based on an assumption that all eligible infertility 
patients in a country in any year would receive an average 
of three funded cycles of in vitro fertilisation (IVF) or 
intracytoplasmic sperm injection (ICSI). This assumption 
is consistent with the support observed by Fauser et al9 as 
well as the most common threshold for publicly funded 
cycles in European countries, although it varies between 
one and six cycles in different countries.15 The number 
of persons—female and male—likely to seek ART was 
based on estimates of reproductive age populations in 
each country and estimates of the prevalence of infer-
tility and the probability of seeking fertility treatment 
from Boivin et al.6 The average cost per cycle of treatment 
was derived from country- specific estimates from IVF 
Worldwide,16 updated to 2020 costs using country- specific 
price indices. The distribution of treatments (IVF or 
ICSI) within this overall average was based on treatment 
proportions observed in human fertility reports from 
UK and Sweden.17–19 The calculated country- specific 
amounts are shown in table 1 in local currency along with 
the equivalent sum in euros (€). Only the local currency 
amount was shown to respondents; euros are included for 
comparability between countries/regions in the analysis 
of responses.
In the second part of the questionnaire, respondents 
who indicated that they had experience with infertility or 
ART participated in a discrete choice experiment (DCE) 
to elicit the relative importance of different aspects of 
ART, including effectiveness, adverse effects and cost. 
This manuscript focuses on the attitudes and WTP of the 
full sample, with the DCE results reported elsewhere.
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Patient and public involvement
There was no patient or public involvement in the design, 
conduct or reporting of this research. We intend to 
disseminate the results of this research via patient advo-
cacy organisations.
Study population
Samples were recruited from survey panels maintained by 
Dynata in the USA, UK, Spain, China, Denmark, Sweden, 
Norway and Finland. These countries were chosen to 
represent a diverse, though by no means comprehensive, 
cross section of attitudes towards infertility and WTP for 
publicly funded fertility treatments.
Individuals who had registered to receive survey invi-
tations from Dynata received an email inviting them to 
learn more about the study. Following the accompanying 
link took them to an online participant information sheet 
which outlined the purpose of the study and provided a 
voluntary link to the questionnaire. Respondents were 
required to check a box indicating their consent to 
participate in the survey before they could proceed to the 
questionnaire. Respondents who submitted a completed 
questionnaire were rewarded by the survey provider 
with ‘points’ that can be accumulated and redeemed for 
rewards. Potential respondents continued to be recruited 
until the predefined sample quotas were met.
A small convenience sample (n=25) was initially 
recruited from each country/region to pilot the survey. 
Respondents completed the survey and were then asked 
to rate the difficulty and length of the survey on a 5- point 
Likert scale, from very easy/short to much too difficult/
long. Dropout rates in each country were also tracked. 
The pilot identified an issue around the currency symbols 
presented to some respondents and this was corrected 
in the final version of the questionnaire. Ratings of the 
length and difficulty of the survey did not flag concerns 
around the perceived length or difficulty, and dropout 
rates were comparable across the countries/regions in 
the sample. Based on these results, we proceeded to the 
main survey.
An age- gender representative sample was recruited 
from each country (or region, in the case of the Nordic 
countries), and this was supplemented by an ‘over- sample’ 
of reproductive age respondents to ensure additional 
statistical power for the DCE phase of the study. To ensure 
the representativeness of the sample, respondent quotas 
in each country were defined by gender and age group, 
and once a demographic quota for the WTP sample was 
filled, it was closed to respondents with the same charac-
teristics. The oversample is excluded from the analysis of 
WTP to maintain national representativeness. Sample size 
in the main survey was informed by Dynata’s advice on 
the number of respondents necessary to ensure reason-
able demographic representativeness in each country.
Statistical analysis
All WTP analyses were based on the nationally representa-
tive sample. Due to the small populations of the individual 
Nordic countries, participants from these countries were 
pooled into a combined Nordic sample that was represen-
tative of the region rather than the individual countries. 
This seemed justifiable given similarities in the way the 
healthcare is organised and funded, as well as expecta-
tions of similar ethical values, across these countries.
Responses to the demographic and attitudinal ques-
tions were descriptively summarised by country but not 
analysed for significant differences between countries. 
For the analysis of dichotomous WTP, a logistic model was 
used to analyse the impact of individual demographics 
and attitudes on individual WTP the threshold amount. 
For the analysis of maximum WTP, a Tobit model was used 
to account for the fact that the dependent variable was 










Mean maximum WTP (95% CI), 
local currency*
Mean maximum WTP 
(95% CI), €*
UK £2.42 2.68 1.11 £4.43 (3.51 to 5.35) 4.91 (3.89 to 5.93)
USA US$6.60 5.57 4.22 US$29.38 (24.27 to 34.49) 24.77 (20.46 to 29.09)
Spain €2.49 2.49 3.00 €8.72 (7.26 to 10.19) 8.72 (7.26 to 10.19)
China ¥22.51 2.72 4.61 ¥281.00 (246.71 to 315.28) 34.07 (29.91 to 38.23)




Full sample‡ – – 3.00   – 15.47 (14.23 to 16.72)
Conversions as of 6 August 2020, https://www.xe.com/.
*Estimates exclude top 1% of maximum WTP responses to trim outliers.
†The Nordic countries use a mix of currencies and cannot be summarised individually.
‡The full data set was used for the calculations of median WTP and the trimmed data set for the calculation of mean WTP.
DKK, Danish krone; NOK, Norwegian krone; SEK, Swedish krona; WTP, willingness to pay.
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meaningfully censored at zero and therefore not normally 
distributed. A Tobit model accounts for censoring in esti-
mates of the regression coefficients and their SEs. The 
top 1% of WTP responses from each country/region were 
excluded from the Tobit analysis to trim extreme outliers. 
Each country/region was analysed separately and statis-
tical significance was judged at the 0.05 level.
RESULTS
The survey was administered online in February 2020 and 
there were a total of 7945 respondents in the age- gender 
nationally representative WTP samples. The number of 
respondents by country is summarised in table 2 along 
with key characteristics. The age distribution of respon-
dents was similar between countries and the most notable 
difference was in the proportion of respondents over the 
age of 60. Older respondents represented roughly 20% 
of the sample from the Nordics, UK and USA, 14% of the 
Spanish sample and 7% of the Chinese sample. Compar-
ison with national age- gender distributions (see online 
supplemental figure 1) showed a reasonable correspon-
dence between national and sample age- gender distri-
butions, although females older that 60 were relatively 
under- represented in all samples, particularly in Spain 
and China. Males older than 60 were also relatively under- 
represented in some samples, but to a lesser extent than 
females.
Attitudes towards infertility and ART eligibility
Respondent attitudes towards infertility are summarised 
in figure 1. In general, there was strong support for state-
ments that infertility is a medical condition (but not an 
illness), that the desire for children is a basic human 
need, that the opportunity to have children should be 
available to everyone and that the infertile should have 
access to treatments that improve the chance of preg-
nancy. Support for ART eligibility by recipient charac-
teristics is summarised in figure 2. Overall support was 
highest for persons with a medical problem preventing 
them from having a baby and lowest for those who already 
have one or more children or have previously received 
ART. Finally, support for ART eligibility by recipient age 
and sex is summarised in figure 3. Support peaked for 
patients between 30 and 39 years old, with support for 
older patients higher than for younger patients. Support 
for female eligibility was slightly but statistically signifi-
cantly higher than for males in all countries/regions.
Dichotomous WTP
Overall, 56.4% of respondents were willing to pay the 
country- specific contribution. WTP was highest in China 
(78.9% of respondents) and Spain (61.9%) while slightly 
less than half of all respondents supported the increase 
in the USA, Nordics and UK (48.8%, 47.6% and 46.7%, 
respectively). The proportion willing to make some 
contribution, even if it was less than the country- specific 
amount, was 73.9% across the sample, ranging from 






or long- term 
relationship*
% tried 
to have a 
baby*








China 1524 46.5 84.4 79.7 61.2 40.3 85.4
Nordics 1894‡ 50.1 63.7 65.9 29.6 15.3 67.6
Spain 1512 51.0 76.0 69.1 48.6 30.5 74.7
UK 1513 51.0 70.5 64.3 37.4 15.6 73.1
USA 1502 52.3 67.7 61.3 40.0 25.2 76.2
*All proportions exclude respondents who declined to answer.
†Conditional on having tried to have a baby.
‡Denmark 512; Finland 512; Norway 360; Sweden 510.
Figure 1 Attitudes towards infertility. Illness: ‘Infertility is an 
illness’. Medical condition: ‘Infertility is a medical condition’. 
Personal matter: ‘Infertility is a personal matter and it is 
ethically wrong to treat it as a medical condition’. Basic 
human need: ‘The desire for children is a basic human need’. 
Opportunity: ‘The opportunity to have children should be 
available to everyone’. Better off: ‘Society is better- off if more 
people can have children’. Access: ‘Infertile women and men 
should have access to treatments that improve their chances 
of pregnancy’.
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93.4% in China to 65.9% in the Nordics (Spain 74.1%; 
USA 70.5%; UK 67.3%).
The predictors of agreement with the dichotomous 
WTP question were similar to the drivers of maximum 
WTP, discussed in more detail below.
Maximum WTP
Maximum WTP by country/region is presented in 
table 1, expressed in local currency and euros for compa-
rability, and shows that respondents from USA (€24.77 
per month) and China (€34.07 per month) had a signifi-
cantly and substantially higher mean maximum WTP 
than respondents from the European countries (between 
€4.91 and €8.72 per month). These figures exclude the 
top 1% of maximum WTP values but the substantial differ-
ence between the mean and median values indicates that 
there are still some extreme responses in the data, partic-
ular among the USA and China samples.
Results of the Tobit regression of maximum WTP 
with respect to respondent characteristics, attitudes 
towards infertility and attitudes towards eligibility are 
illustrated in figures 4–6, respectively. Detailed regres-
sion results by parameter and country/region are avail-
able in the online supplemental material. Figure 4 shows 
that maximum WTP was positively and significantly 
associated with having received fertility treatment in 
the past or knowing someone who had, and negatively 
associated with the respondent’s age. Women tended to 
have a lower maximum WTP than men, controlling for 
education and income. Figure 5 shows that the associa-
tions between attitudes towards infertility and maximum 
WTP were heterogeneous between national samples. In 
particular, USA and China tended to move in opposite 
directions. The greatest divergence was in the associa-
tion between maximum WTP and the statement that all 
people deserve an opportunity for children. Agreement 
dramatically increased maximum WTP in the USA but 
dramatically decreased maximum WTP in China. Finally, 
figure 6 shows that supporting eligibility for anyone who 
has difficulty conceiving, and those without a spouse Figure 3 Support for eligibility by recipient age and sex.
Figure 4 Drivers of maximum willingness to pay (WTP) 
by respondent characteristics. Figure excludes primary 
education category due to small n. ART, assistive 
reproductive therapies.
Figure 2 Support for fertility treatment eligibility. Difficulty: 
‘Anyone who has difficulty having a baby’. Medical problem: 
‘Anyone with a medical problem preventing them from having 
a baby’. No spouse/partner: ‘Anyone without a spouse 
or long- term partner’. Children: ‘Anyone who already has 
one or more children’. Children via ART: ‘Anyone who have 
already had one or more children with assistance of ART’. 
Low chance: ‘Anyone with a low chance of a successful 
pregnancy, even with treatment’. ART, assistive reproductive 
therapies.
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or long- term partner, was associated with a significantly 
greater maximum WTP in almost all countries.
DISCUSSION
Our large, multicountry study found that a majority of 
respondents in our age- gender nationally representative 
public samples agree with infertility as a medical condi-
tion and support the idea that all infertile individuals 
should have access to treatments that improve the chance 
of conception. A majority was also in agreement with the 
idea that the desire for children is a basic human need. 
Importantly, the WTP questions showed that respondents 
also supported some increase in their taxes or insurance 
premiums to fund a national ART programme. A majority 
of respondents in China and Spain supported a contri-
bution that could fund an average of three cycles of ART 
for anyone with infertility, as part of a publicly funded 
national programme. Support for this specific amount 
was weaker in the other countries but there was a majority 
support for at least some public contribution to a national 
ART programme.
This survey extends our understanding of public atti-
tudes towards infertility and WTP for publicly funded 
treatments beyond the strictly European context of 
previous studies8 9 by including the USA and China, 
countries with very different demographic and fertility 
profiles from Europe, and potentially different views 
on infertility and public funding for ART. We followed 
Rauprich et al8 in the design of our WTP questions in elic-
iting dichotomous WTP for a specific monthly contribu-
tion to support a national ART programme. Their finding 
of 57% public WTP was very similar to the 56% overall 
proportion we observed, supporting the robustness of 
this finding, although it is important to note that this level 
of support was not evenly distributed across all countries 
in our sample. Like Rauprich et al8 and Fauser et al,9 we 
also find strong agreement for the notion that all persons 
who have difficulty conceiving should be able to access 
ART and that this support drops for those who already 
have one or more children. Our respondents were consis-
tent in giving greater support to recipients aged 30–39 
over other age groups, particularly recipients less than 20 
or older than 50, and in showing a slight preference for 
female over male recipients. Most respondents favoured 
access for anyone having trouble conceiving, regardless 
of the probability of success, although support fell for 
people who already had children (with or without ART).
Interestingly, agreement with eligibility for respondents 
not in a long- term relationship—a potentially controver-
sial statement—was associated with a statistically signifi-
cantly higher maximum WTP in every sample except the 
UK (where it was positive but insignificant). Eligibility for 
those not in a long- term relationship was supported by 
just over half of the respondents in the sample, although 
it was notably higher in Spain and the USA. We specu-
late this view may represent a strong personal belief in 
universal access to ART and this is reflected in a higher 
WTP for a national programme, but further qualitative 
research would be required to confirm this hypothesis.
Substantive cultural and health system differences 
between the countries in the study make direct compar-
ison between national samples difficult, and the study 
design did not allow us to control for these factors. 
However, some crude country- specific results do stand 
Figure 5 Drivers of maximum willingness to pay (WTP) 
by attitudes towards infertility (vs disagree). ART, assistive 
reproductive therapies.
Figure 6 Drivers of maximum willingness to pay (WTP) by 
agreement towards eligibility (vs disagree). ART, assistive 
reproductive therapies.
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out. Most clearly, the US and Chinese samples stand out 
from the others in terms of their maximum WTP towards 
a publicly funded ART programme. However, some of 
the key drivers of this maximum WTP differed between 
the two samples. The association between maximum 
WTP and agreement with eligibility for individuals who 
already had one or more children was strongly positive in 
the Chinese sample but negative in the US sample. The 
reverse pattern was seen with respect to agreement with 
the statement that all persons deserve an opportunity 
for children, where the association was strongly nega-
tive in the Chinese sample and strongly positive in the 
US sample. A similar but less extreme pattern was seen 
around the association between agreement that society is 
better off if more people can have children: agreement 
was associated with a lower maximum WTP in the Chinese 
sample and a positive WTP in the US sample. The nega-
tive association between maximum WTP and agreement 
with greater opportunities for children in the Chinese 
sample may represent something of a protest response, 
if these respondents felt it should be the state’s respon-
sibility to pay for fertility treatment and were therefore 
less willing to support a specific levy for such treatments. 
This is speculation, but these patterns do highlight differ-
ences in cultural attitudes towards aspects of infertility 
and, arguably, the role of public funding of ART, between 
countries in the study.
More than half of the Chinese respondents expressed 
support for the notion of infertility as a medical condition 
and as a personal matter that should not be treated as a 
medical condition. This contradictory result, combined 
with a high degree of support in the dichotomous WTP 
question, may suggest some degree of acquiescence, or 
‘yea- saying’, bias among Chinese respondents, by which 
some respondents have a tendency to favour positive 
responses.20 However, there was also a slightly higher 
proportion of younger respondents in the Chinese sample 
relative to the other counties, and this was associated with 
a higher WTP relative to older age groups. More broadly, 
table 2 suggests a high proportion of respondents across 
all countries reported having tried to have a baby and 
having received medical assistance, particularly in the 
Chinese sample. These rates suggest that individuals with 
experience with ART may have been more motivated 
to participate in the survey and therefore may be over- 
represented in the sample.
The potential for hypothetical or protest responses 
is a limitation of most contingent valuation (WTP) 
studies.21 22 Other studies of WTP in the context of 
infertility have attempted to elicit maximum WTP from 
a recipient perspective and have reported strong start 
point or framing effects using payment card and open- 
ended elicitation formats.10–13 We sought to minimise 
these sources of bias by eliciting dichotomous WTP for 
a small, monthly figure rather than a larger and poten-
tially more abstract annual figure. We also framed the 
question around a concrete and policy- relevant figure 
rather than attempting to elicit naive maximum WTP 
values. We believe this more conservative approach to 
estimating WTP enhances the robustness of the results. 
We caution that our subsequent estimates of maximum 
WTP are likely to be anchored on the figure presented 
in initial dichotomous question. We also trimmed the 
top 1% of maximum WTP values to reduce the impact 
of extreme responses, although the substantial difference 
between mean and median maximum WTP indicates that 
some extreme values remain. This highlights the tension 
between excluding implausible or protest responses 
without imposing research expectations and respecting 
individual rationality.23 In the absence of an objective 
indication that a specific response may be irrational or 
unconsidered, we chose to include the broadest sample 
possible. We note that dichotomous and maximum WTP 
increased with respondent income quintile, consistent 
with economic theory and supporting the face validity of 
the results.
An additional limitation is that our estimates of the per- 
capita cost of national ART programmes in the different 
study countries, which encompass very different health 
systems and funding mechanisms, are relatively crude. The 
estimates were further complicated by the wide range of 
public and private prices for ART in most countries. The 
purpose of these calculations was not to estimate a per- 
capita cost of an ART programme in each country but to 
generate reasonably comparable reference points to esti-
mate dichotomous WTP in each country. It is likely that 
the precise per- capita cost of a national ART programme 
in any specific study country will be more or less than 
the sum we presented to respondents. This is particu-
larly true for the Nordic estimate, which is not specific to 
any of the component countries. Future research should 
seek to more precisely estimate the cost of national ART 
programmes based on country- specific ART cost per cycle 
and rates of infertility and care seeking. This last param-
eter is itself likely to be dependent on the existence of 
publicly funded treatment options, further complicating 
the estimation.
Fertility rates in most wealthy countries have fallen 
below population replacement levels and governments 
are having to consider different aspects of their ‘popula-
tion policy mix’, including improving access to ART.1 5 7 
This study builds on previous findings and confirms strong 
support for the principle of universal ART access for all 
infertile individuals across all the countries in the survey. 
Importantly, it also demonstrates that most respondents 
support at least some increase in their taxes or insurance 
premiums to fund this access.
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